Bio-Techne ( TECH ) Q4 EPS Rises 8.2%
Bio-Techne ( NASDAQ:TECH ) , a leading provider of life sciences tools and diagnostic solutions, reported its earnings for the fourth quarter of fiscal 2025 on August 6, 2025. The company's headline news was a modest beat on both revenue and non-GAAP earnings per share, with GAAP revenue of ...
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
Exosome Research Market is expected to generate a revenue of USD 646.52 Million by 2032, Globally, at 13.93% CAGR: Verified Market Research®
Lewes, Delaware, June 19, 2025 ( GLOBE NEWSWIRE ) -- The Global Exosome Research Market Size is projected to grow at a CAGR of 13.93% from 2026 to 2032, according to a new report published by Verified Market Research®.
This PVH Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Commercial Metals ( NYSE:CMC ) , Brixmor Property Group ( NYSE:BRX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Tom Nikic initiated coverage on Columbia Sportswear Company COLM with a Hold ...
What Does the Market Think About Bio-Techne? - Bio-Techne ( NASDAQ:TECH )
Bio-Techne's TECH short percent of float has risen 12.34% since its last report. The company recently reported that it has 7.20 million shares sold short, which is 5.28% of all regular shares that are available for trading.
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment in third-quarter fiscal 2025.
Is the Options Market Predicting a Spike in BioTechne Stock?
Investors need to pay close attention to TECH stock based on the movements in the options market lately.
This House of Representative Just Bought Up To $195K In Bio-Techne Stock - Bio-Techne ( NASDAQ:TECH ) , Dayforce ( NYSE:DAY )
A report on May 2, 2025 shows that Representative April McClain Delaney from Maryland purchase stock in Bio-Techne TECH, valued between $13,013 and $195,000. According to the May filing, the transaction occurred on May 2, 2025. At the time of writing, Bio-Techne shares are trading up 0.41% at $50.7.
TECH Gears Up to Report Q3 Earnings: Here's What to Expect
Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and a rise in biotech customers' ordering trends in the fiscal third quarter.
Strength Seen in Bio-Techne ( TECH ) : Can Its 10.8% Jump Turn into More Strength?
Bio-Techne (TECH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Host Hotels & Resorts ( NASDAQ:HST ) , Health Catalyst ( NASDAQ:HCAT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Paul Knight downgraded the rating for Bio-Techne Corporation TECH from ...
Bio-Techne Opens New Customer Experience Centre in Germany
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
TECH Stock Might Rise Following the Leo Shipping Announcement
Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.
Techne ( TECH ) Down 15.5% Since Last Earnings Report: Can It Rebound?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Techne ( TECH ) Down 15.5% Since Last Earnings Report: Can It Rebound?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.
Is the Market Bullish or Bearish on Bio-Techne? - Bio-Techne ( NASDAQ:TECH )
Bio-Techne's TECH short percent of float has risen 29.12% since its last report. The company recently reported that it has 5.08 million shares sold short, which is 3.68% of all regular shares that are available for trading.
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - CervoMed ( NASDAQ:CRVO ) , Qiagen ( NYSE:QGEN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Catherine Schulte downgraded the rating for Qiagen N.V.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
The Zacks Analyst Blog Highlights Boston Scientific, Hologic, BioTechne, STERIS and Align
Boston Scientific, Hologic, BioTechne, STERIS and Align are included in this Analyst Blog.
Can These 5 MedTech Stocks Hit Earnings Targets This Season?
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.
TECH Gears Up to Report Q2 Earnings: Here's What to Expect
In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.
( TECH ) - Analyzing Bio-Techne's Short Interest - Bio-Techne ( NASDAQ:TECH )
Bio-Techne's TECH short percent of float has risen 7.35% since its last report. The company recently reported that it has 4.05 million shares sold short, which is 2.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.95 days to cover ...
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.
Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?
TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.
ScaleReady awards a G-Rex® Grant to Moonlight Bio - Bio-Techne ( NASDAQ:TECH )
ST. PAUL, Minn., Dec. 18, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation TECH and CellReady, today announced that Moonlight Bio has been awarded a G-Rex® Grant.
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.
Should You Continue to Retain Bio-Techne Stock in Your Portfolio?
Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.
Techne ( TECH ) Up 2.2% Since Last Earnings Report: Can It Continue?
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH - Bio-Techne ( NASDAQ:TECH )
MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation TECH today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease.
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued momentum across its Diagnostics & Spatial Biology segment.
What to Expect From These 3 MedTech Stocks This Earnings Season
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
Immunoassay Market to Surpass Market Valuation of USD 54.27 Billion by 2031 | SkyQuest Technology
Westford, USA, Oct. 24, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Immunoassay Market will reach a value of USD 54.27 Billion by 2031, with a CAGR of 5.59% during the forecast period ( 2024-2031 ) .
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards?
Within Spatial Biology, TECH is expected to have recorded strong growth, banking on the strong adoption of its new spatial biology instrument COMET.
Cell Expansion Market Size to Reach USD 40.1 billion, Advancing at a CAGR of 12.1% by 2034: Exclusive Report by Transparency Market Research, Inc.
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- The global cell expansion market ( 세포 확장 시장 ) is estimated to flourish at a CAGR of 12.1% from 2024 to 2034.
ScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine - Bio-Techne ( NASDAQ:TECH )
ST. PAUL, Minn., Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation TECH and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine ( LCGM ) ...
New Strong Sell Stocks for August 23rd
ARCO, BMTX and TECH have been added to the Zacks Rank #5 (Strong Sell) List on August 23, 2024.
Apoptosis Assays Market Projected to Expand at a CAGR of 8.5%, Elevating to a Valuation of USD 11.3 billion by 2034 | Analysis by Transparency Market Research Inc.
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- The global apoptosis assay market ( 세포사멸 분석 시장 ) was projected to attain US$ 4.6 billion in 2023. It is likely to garner an 8.5% CAGR from 2024 to 2034, and by 2034, the market is ...
John L Higgins At Bio-Techne Capitalizes: Options Exercised, Resulting In $300K - Bio-Techne ( NASDAQ:TECH )
Highlighted on July 10, it was unveiled in an SEC filing that Higgins, Director at Bio-Techne TECH, executed a significant transaction involving the exercise of company stock options. What Happened: In an insider options sale disclosed in a Form 4 filing on Wednesday with the U.S.
Illumina To Spin-Off GRAIL Unit On June 24
On June 3, 2024, Illumina's ( NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion ) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on the timeline.
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy ( CGT ) Development and Manufacturing
ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy ( CGT ... PR ...
Epigenetics Market size is set to grow by USD 1.47 billion from 2024-2028, Rising epigenetic applications in non ... - PR Newswire
Epigenetics Market size is set to grow by USD 1.47 billion from 2024-2028, Rising epigenetic applications in non ... PR ...
IBD Rating Upgrades: Bio-Techne Shows Improved Relative Price Strength
The Relative Strength ( RS ) Rating for Bio-Techne ( TECH ) climbed into a higher percentile Wednesday, as it got a lift from 68 to 72. X IBD's proprietary rating measures market leadership with a 1 ( worst ) to 99 ( best ) score.
Bio-Techne Trying To Close In On Key Technical Measure
Bio-Techne ( TECH ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Friday, rising from 65 to 71. X This proprietary rating tracks technical performance by using a 1 ( worst ) to 99 ( best ) score that identifies how a stock's price performance over the trailing 52 weeks ...
5 Stocks at the Forefront of S&P 500 ETF's Latest Rally
The S&P 500 is up for the fourth consecutive session. While many stocks have powered the ETF, we have highlighted five that have led the way higher.
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
NEW YORK, May 06, 2024 ( GLOBE NEWSWIRE ) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference happening on Tuesday & Wednesday, May 21st - 22nd, 2024.
